Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Domainex Launches Discovery STAR Award

Published: Tuesday, January 22, 2013
Last Updated: Tuesday, January 22, 2013
Bookmark and Share
Domainex Ltd is launching its Discovery STAR Award to support academic groups at the early stages of drug discovery.

Domainex’s STAR Award scheme will provide successful applicants with virtual hit screening using Domainex’s LeadBuilder platform and/or drug discovery consultancy services. The aim will be to bridge a current ‘funding gap’ for these activities, thereby allowing projects to progress to an inflection point that is suitable for larger external grant-funding schemes such as the TSB/MRC Biomedical Catalyst Fund, The Wellcome Trust’s SDDI scheme, European Union FP7, and MRC DPFS.  

Translational research is the conversion of early-stage discoveries into new health products. Domainex is a leader in the support of academic translational research and has secured funding with numerous groups at the forefront of drug target research. Once funding is in place, and in full collaboration with the academic partner, Domainex has then deployed its own capabilities in medicinal and computational chemistry, biochemistry and DMPK testing to progress hit compounds through to the identification of clinical candidate drugs.

Eddy Littler, Chief Executive Officer of Domainex, said: “Domainex has successfully supported numerous academic groups across Europe and UK to apply for drug discovery funding from a range of sources – these include The Institute of Cancer Research; St. George’s, University of London; and the University of Manchester. However, small-molecule hits are typically required before funding can be secured, and the application process can be challenging for those without a commercial background. Domainex’s Discovery STAR Award will enable this gap to be filled for the selected recipients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Domainex, Cresset Announce Drug Discovery Services Alliance
Domainex Ltd., a small-molecule drug discovery company, and Cresset Discovery Services, a services company for small molecule discovery and design, have announced an alliance to provide their customers with world-class laboratory-based and computational drug discovery services through a seamless combination of their respective capabilities in chemistry and biology.
Tuesday, January 26, 2016
Domainex and Ark Therapeutics Extend Drug Discovery Agreement
Domainex continues providing Ark with hit-finding and lead optimization services for drug discovery against exciting therapeutic targets.
Thursday, July 09, 2009
Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
‘Precision Prevention’ for Colorectal Cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Spotting DNA Repair Genes Gone Awry
Ludwig researchers develop a two-pronged approach for identifying genes responsible for fixing DNA damage that can trigger cancer when compromised.
Interpreting “Dark Matter” DNA
Scientists at the Gladstone Institutes have invented a new way to read and interpret the human genome.
A Programming Language for Living Cells
New language lets researchers design novel biological circuits.
The Epigenetics of Childhood Cancer
Qlucore software enables researchers to more easily study the genetic influences behind childhood cancer.
Mining Whole Exome Data to Improve Cancer Therapies
New tool interprets the raw data of whole exome tumor sequencing and then matches the cancer’s unique genetics to FDA-approved targeted treatments.
Pittcon 2016: Accelerating Innovation And Enhancing Productivity With Technology
Collaboration and externalization of data highlight evolving lab operations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!